Abstract titles reveal some of ASCO’s key datasets.

Amid doubts about early data with FG-3246, the group is scathing about its rivals.

More efficient internalisation and release – not bystander activity – are the focus for this private ADC player.

An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.

The company looks rash for promising Tamarack data at the conference, although at least vobra duo’s safety has improved.

Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.

A roundup of the first quarter's key oncology drug approvals and rejections.

Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.